Therefore, it becomes increasingly important to address the combined effect of agents targeting cardinal regulatory proteins of mitosis, such as Plk1, with conventional treatment modalities, in order to further improve outcome of patients diagnosed with NSCLC. This evidence concerns the gene PLK1 and non-small cell lung carcinoma.